会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Combination cancer therapy with bis(thiohydrazide) amide compounds
    • 联合癌症治疗与双(硫代酰肼)酰胺化合物
    • US08017654B2
    • 2011-09-13
    • US11918357
    • 2006-04-13
    • Thomas A. DahlMatthew McLeod
    • Thomas A. DahlMatthew McLeod
    • A01N37/18A61K31/16C07D305/00C07D407/00C07D493/00C07C241/00C07C243/00C07C249/00C07C251/00
    • A61K45/06A61K31/16A61K31/165A61K31/337A61K2300/00
    • A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
    • 用癌症治疗受试者的方法包括在三至五周内共同给予受试者的步骤,量为约243μmol/ m 3至315μmol/ m 2的紫杉烷(例如,相当于约210的紫杉醇 -270 mg / m2); 和约1473μmol/ m 2与约1722μmol/ m 2之间的量的二(硫代酰肼)酰胺(例如化合物(1),约590-690mg / m 2)。 双(硫代酰肼)由结构式(I)表示,Y为共价键或任选取代的直链烃基,或Y与它们所键合的两个> C = Z基团一起为 任选取代的芳族基团。 R 1 -R 4独立地是-H,任选取代的脂族基团,任选取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H,任选取代的脂族基团或任选取代的芳基。 Z是O或S.
    • 3. 发明授权
    • Method and apparatus for study of gas-phase and gas-borne agents
    • 气相和气体介质的研究方法和装置
    • US5308758A
    • 1994-05-03
    • US959311
    • 1992-10-09
    • Thomas A. Dahl
    • Thomas A. Dahl
    • C12M1/04C12M3/06C12Q1/24
    • C12M41/46
    • Method and apparatus for exposing biological materials to gas-phase or gas-borne agents, including the steps of providing a chamber for supporting said biological materials, said chamber including wicking means configured and arranged to hold said biological materials and provide said cells with a wetting medium while allowing said gas-phase or gas-borne agents to directly interact with said biological materials, humidifying said chamber to a humidity between 95% and 100%, inclusive, placing said biological materials in said chamber on said wicking means, exposing said biological materials in said chamber to one or more said gas-phase or gas-borne agents while maintaining said humidity between 95% and 100%, inclusive, and assessing the effect of said exposing on said biological materials.
    • 用于将生物材料暴露于气相或气体传播剂的方法和装置,包括提供用于支撑所述生物材料的室的步骤,所述室包括芯吸装置,其被配置和布置成保持所述生物材料并向所述细胞提供润湿 培养基,同时允许所述气相或气体传播剂与所述生物材料直接相互作用,将所述室加湿至95%至100%之间的湿度,包括将所述生物材料置于所述室中的所述芯吸装置上,暴露所述生物 将所述室中的物质与一种或多种所述气相或气体载体物质保持在一起,同时保持所述湿度在95%至100%之间,并评估所述暴露对所述生物材料的影响。
    • 5. 发明申请
    • Combination cancer therapy with bis(thiohydrazide) amide compounds
    • 联合癌症治疗与双(硫代酰肼)酰胺化合物
    • US20090137682A1
    • 2009-05-28
    • US11918357
    • 2006-04-13
    • Thomas A Dahl
    • Thomas A Dahl
    • A61K31/165A61P35/00
    • A61K45/06A61K31/16A61K31/165A61K31/337A61K2300/00
    • A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
    • 用癌症治疗受试者的方法包括在三至五周内共同施用受试者的步骤,量为约243mol / m 2至315mol / m 2的紫杉烷(例如,相当于约210的紫杉醇 -270 mg / m2); 和约1473μmol/ m 2和约1722μmol/ m 2之间的量的二(硫代酰肼)酰胺(例如化合物(1),约590-690mg / m 2)。 双(硫代酰肼)由结构式(I)表示,Y为共价键或任选取代的直链烃基,或Y与它们所键合的两个> C = Z基团一起为 任选取代的芳族基团。 R 1 -R 4独立地是-H,任选取代的脂族基团,任选取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H,任选取代的脂族基团或任选取代的芳基。 Z是O或S.